BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus

Could Cynata’s Cymerus™ Platform Be A Tool in the War Against Coronavirus?

By Leave a Comment

What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.

The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]

Funding for COVID-19 Countermeasures: Diagnostics, Vaccines, Treatments

By Leave a Comment

COVID-19 is a global emergency of unprecedented scale. Affecting all 7.2 billion people worldwide, it is largest pandemic in modern history. Because it could take a year or two before vaccines get approved, manufactured at high volume, and distributed on a global scale, there’s a dire need for treatments to reduce the mortality rate of the coronavirus while we wait. To this end, agencies around the world have been rapidly announcing funding support for the development of diagnostics, vaccines and therapeutics against COVID-19. [Read more…]

Mesoblast to Enroll 300 Patients in COVID-19 Trial of Stem Cell Therapy Remestemcel-L

By 1 Comment

Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

NEW YORK, April 30, 2020 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. [Read more…]

Stem Cells for Coronavirus: Could Cells Be The Cure?

By 1 Comment

Coronavirus disease (COVID-19) is an emerging global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019 and by March 2020 it was reported that it had spread to several countries across the world. [Read more…]

Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19

By 2 Comments

MIAMI, May 05, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. [Read more…]

BioInformant's World-Class Clients

Shopping cart0
There are no products in the cart!
Continue shopping
0